A multicenter randomized controlled trial is conducted to evaluate the efficacy of a novel… — USMLE Step 3

A multicenter randomized controlled trial is conducted to evaluate the efficacy of a novel anti-fibrotic agent compared with standard of care for patients with idiopathic pulmonary fibrosis. The primary outcome is disease progression, defined as an absolute decline of $\geq$ 10% in forced vital capacity (FVC) over $52$ weeks. The initial unadjusted analysis reveals a relative risk ( $RR$ ) of $0.68$ ( $95\%$ $CI$ : $0.54-0.85$ ) for disease progression in the novel agent group compared with standard of care.

During the analysis phase, the researchers stratify the trial results based on the presence or absence of the MUC5B promoter genetic variant. The stratified analysis yields the following results:
- MUC5B variant present: $RR = 0.32$ ( $95\%$ $CI$ : $0.21-0.49$ )
- MUC5B variant absent: $RR = 1.05$ ( $95\%$ $CI$ : $0.81-1.36$ )

Based on these findings, which of the following is the most appropriate way to interpret and report these data?

A
Calculate and report a single pooled, adjusted relative risk because the genetic variant is a confounding variable.
B
Report the unadjusted relative risk of 0.68 as the primary finding because the study's randomization inherently eliminates both confounding and effect modification.
Report the relative risks for each genetic stratum separately because the variant modifies the medication's efficacy.Answer
D
Design future trials to match participants based on their genetic variant status to eliminate its confounding effect.
E
Restrict the final analysis strictly to the cohort lacking the genetic variant to avoid selection bias in the efficacy estimate.

Answer

Report the relative risks for each genetic stratum separately because the variant modifies the medication's efficacy.

The correct answer accurately identifies that the MUC5B genetic variant is acting as an effect modifier, not a confounder. In epidemiology, a stratified analysis is used to differentiate between confounding and effect modification. If the stratum-specific relative risks are similar to each other but notably different from the crude relative risk, confounding is present. However, if the stratum-specific relative risks are significantly different from one another (as seen here with

0.32

vs.

1.05

), effect modification is present. Because effect modification represents a true biological interaction—meaning the drug is highly effective in patients with the variant but ineffective in those without it—it is not an error to be 'adjusted away.' Instead, the proper statistical approach is to report the stratum-specific results separately to inform clinical decision-making.

Step-by-Step Solution

Analyze the relationship between the crude relative risk and the stratum-specific relative risks.

The crude

RR

0.68

. The stratum-specific

RR

s are

0.32

and

1.05

. They are significantly different from each other.

Comparing crude and stratified estimates is the primary method to distinguish between confounding and effect modification.

Determine the epidemiological phenomenon present based on the stratified analysis.

Because the

RR

is substantially different depending on the presence or absence of the genetic variant, the variant is an effect modifier.

Effect modification (or interaction) occurs when the magnitude of the effect of an exposure on an outcome differs depending on the level of a third variable.

Identify the correct reporting strategy for this phenomenon.

The investigators should report the stratum-specific relative risks separately.

Unlike confounding, which is a nuisance variable that investigators try to control for (e.g., by pooling), effect modification is a real biological phenomenon that provides valuable clinical information and must be reported separately.

Key Concept

Effect modification occurs when the effect of an exposure on an outcome varies depending on the level of a third variable. It is identified when stratified analysis reveals significantly different relative risks between strata, and it should be reported by providing the stratum-specific results separately.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic